Co-encapsulation of Rifampicin and Isoniazid in Crude Soybean Lecithin Liposomes

Nkanga, Christian Isalomboto; Siwe‐Noundou, Xavier; Walker, Roderick B.; Krause, Rui Werner Maçedo

doi:10.17159/0379-4350/2019/v72a11

Cited by 7 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particle size and zeta potential are two important parameters for maintaining in vivo integrity and behavior of nanoparticles. These observed negative zeta potentials are in line with what has been reported in previous studies using crude soy lecithin and a thin-film hydration method [23,30].…”

Section: Particle Size and Zeta Potentialsupporting

confidence: 92%

See 1 more Smart Citation

Ultrasound-Triggered Release of 5-Fluorouracil from Soy Lecithin Echogenic Liposomes

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer is the third most diagnosed cancer and the second leading cause of death. The use of 5-fluorouracil (5-FU) has been the major chemotherapeutic treatment for colorectal cancer patients. However, the efficacy of 5-FU is limited by drug resistance, and bone marrow toxicity through high-level expression of thymidylate synthase, justifying the need for improvement of the therapeutic index. In this study, the effects of ultrasound on echogenic 5-FU encapsulated crude soy liposomes were investigated for their potential to address these challenges. Liposomes were prepared by thin-film hydration using crude soy lecithin and cholesterol. Argon gas was entrapped in the liposomes for sonosensitivity (that is, responsiveness to ultrasound). The nanoparticles were characterized for particle size and morphology. The physicochemical properties were also evaluated using differential scanning calorimetry, Fourier transform infrared and X-ray diffraction. The release profile of 5-FU was assessed with and without 20 kHz low-frequency ultrasound waves at various amplitudes and exposure times. The result reveal that 5-FU-loaded liposomes were spherical with an encapsulation efficiency of approximately 60%. Approximately 65% of 5-FU was released at the highest amplitude and exposure time was investigated. The results are encouraging for the stimulated and controlled release of 5-FU for the management of colorectal cancer.

show abstract

Section: Particle Size and Zeta Potentialsupporting

confidence: 92%

“…The in vitro release of 5-FU was compared to that from liposomes containing 5-FU in HPLC grade water. The 5-FU content was determined using the method described by Nkanga et al [30], with some changes in the aliquot and concentrations considered.…”

Section: In Vitro Release Of 5-fumentioning

confidence: 99%

Ultrasound-Triggered Release of 5-Fluorouracil from Soy Lecithin Echogenic Liposomes

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, combination therapy is considered an effective strategy to treat multidrug-resistant bacterial infections. The administration of combined drugs in a single vehicle enables the synergistic action of the different mechanisms of action, the delivery of the drugs to the infection sites, the proper exposure of patients to the drug, and the reduced stimulus for developing bacterial resistance [ 46 , 106 ], making co-encapsulation in chitosan-coated zein nanoparticles a promising alternative for resistant respiratory and intestinal infections.…”

Section: Discussionmentioning

confidence: 99%

Ceftazidime/Tobramycin Co-Loaded Chitosan-Coated Zein Nanoparticles against Antibiotic-Resistant and Biofilm-Producing Pseudomonas aeruginosa and Klebsiella pneumoniae

Campos,

Neto,

Scavuzzi

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

This study aimed to co-encapsulate ceftazidime and tobramycin in zein nanoparticles coated with chitosan and to characterize and evaluate the antibacterial and antibiofilm activity against antibiotic-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. Zein nanoparticles, synthesized using the nanoprecipitation method, were characterized by their particle size (Ø), polydispersity index (PDI), zeta potential (ζ), pH, and encapsulation efficiency (%EE). The chitosan coating provided stability, and physicochemical analyses revealed chemical interactions, efficient drug encapsulation, and thermal stability. The release kinetics demonstrated controlled release in simulated gastric and intestinal pH. The antibacterial activity, assessed by minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC), indicated effectiveness against both pathogens. Antibiofilm assays, conducted using the crystal violet method, demonstrated the inhibition and eradication of biofilms. The chitosan-coated zein nanoparticles with CAZ and/or TOB exhibited Ø (315–335 nm), PDI (<0.2), ζ (+40 to +50 mV), pH (5), and %EE (>55%). Notably, the co-encapsulation formulation (CAZ–TOB–ZNP–CH) showed enhanced antibacterial and antibiofilm activities compared to the individual formulations. These findings suggest that the developed nanoparticles present a promising alternative for treating respiratory and intestinal infections caused by antibiotic-resistant and biofilm-producing P. aeruginosa and K. pneumoniae.

show abstract

“…The feasibility of using crude soybean lecithin for preparation of combination products for liposomal dual delivery was demonstrated [89] Crude soybean lecithin…”

Section: Inclusion Complexes Of Cyclodextrin With Isoniazid-grafted Zinc Phthalocyaninementioning

confidence: 99%

Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

The antimicrobial drugs currently used for the management of tuberculosis (TB) exhibit poor bioavailability that necessitates prolonged treatment regimens and high dosing frequency to achieve optimal therapeutic outcomes. In addition, these agents cause severe adverse effects, as well as having detrimental interactions with other drugs used in the treatment of comorbid conditions such as HIV/AIDS. The challenges associated with the current TB regimens contribute to low levels of patient adherence and, consequently, the development of multidrug-resistant TB strains. This has led to the urgent need to develop newer drug delivery systems to improve the treatment of TB. Targeted drug delivery systems provide higher drug concentrations at the infection site, thus leading to reduced incidences of adverse effects. Lipid-based nanocarriers have proven to be effective in improving the solubility and bioavailability of antimicrobials whilst decreasing the incidence of adverse effects through targeted delivery. The potential application of lipid-based carriers such as liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, nano and microemulsions, and self-emulsifying drug delivery systems for the treatment of TB is reviewed herein. The composition of the investigated lipid-based carriers, their characteristics, and their influence on bioavailability, toxicity, and sustained drug delivery are also discussed. Overall, lipid-based systems have shown great promise in anti-TB drug delivery applications. The summary of the reviewed data encourages future efforts to boost the translational development of lipid-based nanocarriers to improve TB therapy.

show abstract

Co-encapsulation of Rifampicin and Isoniazid in Crude Soybean Lecithin Liposomes

Cited by 7 publications

References 38 publications

Ultrasound-Triggered Release of 5-Fluorouracil from Soy Lecithin Echogenic Liposomes

Ultrasound-Triggered Release of 5-Fluorouracil from Soy Lecithin Echogenic Liposomes

Ceftazidime/Tobramycin Co-Loaded Chitosan-Coated Zein Nanoparticles against Antibiotic-Resistant and Biofilm-Producing Pseudomonas aeruginosa and Klebsiella pneumoniae

Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review

Contact Info

Product

Resources

About